Adhesion molecules of the alpha-4-integrin pathway have been evaluated in the treatment of IBD, but unfortunately, unselective block of alpha-4-integrin by natalizumab led to reports of lethal viral encephalopathy. The gene discussed is ITGA4; the disease is inflammatory bowel disease.